VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 83.43 percent increase over losses of $(1.75) per share from the same period last year. The company reported quarterly sales of $121.00 thousand which beat the analyst consensus estimate of $110.00 thousand by 10.00 percent. This is a 6.14 percent increase over sales of $114.00 thousand the same period last year.